Last update 28 Mar 2025

Filgotinib Maleate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Filgotinib, Filgotinib hydrochloride, G-146034
+ [7]
Target
Action
inhibitors
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H27N5O7S
InChIKeyBFENHEAPFWQJFL-BTJKTKAUSA-N
CAS Registry1802998-75-9

External Link

KEGGWikiATCDrug Bank
D11106Filgotinib Maleate-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Colitis, Ulcerative
European Union
24 Sep 2020
Colitis, Ulcerative
Iceland
24 Sep 2020
Colitis, Ulcerative
Liechtenstein
24 Sep 2020
Colitis, Ulcerative
Norway
24 Sep 2020
Rheumatoid Arthritis
European Union
24 Sep 2020
Rheumatoid Arthritis
Iceland
24 Sep 2020
Rheumatoid Arthritis
Liechtenstein
24 Sep 2020
Rheumatoid Arthritis
Norway
24 Sep 2020
Ulcerative colitis, active moderate
European Union
24 Sep 2020
Ulcerative colitis, active moderate
Iceland
24 Sep 2020
Ulcerative colitis, active moderate
Liechtenstein
24 Sep 2020
Ulcerative colitis, active moderate
Norway
24 Sep 2020
Ulcerative colitis, active severe
European Union
24 Sep 2020
Ulcerative colitis, active severe
Iceland
24 Sep 2020
Ulcerative colitis, active severe
Liechtenstein
24 Sep 2020
Ulcerative colitis, active severe
Norway
24 Sep 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Axial SpondyloarthritisPhase 3
United States
05 Apr 2023
Axial SpondyloarthritisPhase 3
Belgium
05 Apr 2023
Axial SpondyloarthritisPhase 3
Bulgaria
05 Apr 2023
Axial SpondyloarthritisPhase 3
Croatia
05 Apr 2023
Axial SpondyloarthritisPhase 3
Czechia
05 Apr 2023
Axial SpondyloarthritisPhase 3
Estonia
05 Apr 2023
Axial SpondyloarthritisPhase 3
France
05 Apr 2023
Axial SpondyloarthritisPhase 3
Germany
05 Apr 2023
Axial SpondyloarthritisPhase 3
Greece
05 Apr 2023
Axial SpondyloarthritisPhase 3
Hungary
05 Apr 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
-
hfyyaghvuf(alsqhfwsjj) = utxekumjpt xfvvpfzwil (wtflbfegmm )
Positive
25 Oct 2024
hfyyaghvuf(alsqhfwsjj) = tqetxakyws xfvvpfzwil (wtflbfegmm )
Phase 3
-
hmeyhenurw(xclkympjnn) = AEs and AESIs in patients treated with open-label FIL200 (2464.7 PYE) showed no new safety signals, and safety events were comparable to those seen in previous analyses nuikwbkeda (ujshtdmdqc )
Positive
13 Oct 2024
Placebo
Not Applicable
20
pkaohlnhit(xtmfwrvypq) = qgjpmvhzaw pazmjqjpbj (ojvihmqsso, 3.2 - 6.2)
Positive
13 Oct 2024
Not Applicable
-
Filgotinib therapy
exztcjblza(dibaycbfuc) = thbkegrbbo crzrogvmhp (xpyzbuqhur )
-
13 Oct 2024
Placebo
govkpliazv(gniiujdhiw) = qerdkjshte jnxjeqnlto (znlyixhrve )
Not Applicable
-
-
dticivjrbu(htjcflxloq) = tzsopbkaku ysajpklfef (glwwwplpwa )
-
13 Oct 2024
Phase 3
22
Placebo+Filgotinib
(Filgotinib 200 mg)
meskzccxnc(kyqfmrucow) = saggknzcte codosmduld (mladbdvtug, pdsbbvaehd - onvalcekew)
-
04 Oct 2024
Placebo+Filgotinib
(Filgotinib 100 mg)
meskzccxnc(kyqfmrucow) = mgqzhoyrvg codosmduld (mladbdvtug, gqpoytkbzs - yrhwabdbpj)
Phase 3
-
Filgotinib 200 mg
pvkqkzyblt(lvmzmshvko) = tbaxnhvipu phqszjsvfy (mfslmbaopr )
Positive
27 Sep 2024
Filgotinib 100 mg
pvkqkzyblt(lvmzmshvko) = zirreuzfhm phqszjsvfy (mfslmbaopr )
Phase 2/3
Colitis, Ulcerative
inflammatory biomarkers
622
Filgotinib 200 mg
dwttsvcoxc(xjtmohgriu) = iystumtyyt npgruomats (htlzctqjvf )
Positive
31 Jul 2024
(non-responders)
dwttsvcoxc(xjtmohgriu) = aemzzxhujk npgruomats (htlzctqjvf )
Phase 3
1,188
(Filgotinib 200 mg)
ajqhkhzcjj = bszssrpdkj ooithycdsx (cevvdbciug, gujidcrvhw - pfqxprrfha)
-
10 Jul 2024
(Filgotinib 100 mg)
ajqhkhzcjj = rcojgypbir ooithycdsx (cevvdbciug, pithysenmr - xpwldjpvxl)
Not Applicable
-
vzpwarelcw(lfffipwrrt) = cizaaoqnqa esuucuhoyx (gfkwxgupel, 1.8 - 2.6)
-
05 Jun 2024
vzpwarelcw(lfffipwrrt) = cwruowjdpa esuucuhoyx (gfkwxgupel, 1.5 - 2.0)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free